iwCAR-T 2019 | Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts

David Maloney, John Gribben and Saar Gill

John Gribben, MD, DSc , FRCPath, FMed Sci, Barts Cancer Institute, London, UK, is joined by Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA, and David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, to share their highlights from day 2 of the 1st International Workshop on CAR-T (iwCAR-T), held in Miami, FL. The speakers discuss difficulties in targeting acute myeloid leukemia (AML), CAR T-cell therapy in multiple myeloma and clinical trial regulations in China. Allogeneic CAR-Ts are also touched upon.

Share this video